Hypoglycaemia and its consequences
In collaboration with Novo Nordisk, Amylin Pharmaceuticals and University of Leicester, Prof. Paul is leading a research project to evaluate the risk factors associated with mild-moderate and severe hypoglycaemia, and the long-term consequences of hypoglycaemia.
The first real-world based study evaluating the cardiovascular consequences of hypoglycaemia in both type 1 and type 2 diabetes patients was published in Diabetes Care 2015; 38: 316-22. The possible risk factors associated with hypoglycaemia differentiated between patients treated with insulin and incretin-based therapies was published in Journal of Diabetes 2015; 7: 60-7
Prof Sanjoy Paul, Director
Professor Kamlesh Khunti, University of Leicester, UK
Industry grants from Novo Nordisk and Amylin Pharmaceuticals
- Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316-22.
- Paul SK, Maggs D, Klein K, Best JH. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. Journal of diabetes. 2015;7(1):60-7.